Insufficient supply of zoster vaccine until 2014: CSL

Zostavax was recommended by the PBAC in 2008 for the over-60s with a catch-up program for those aged 61 to 79. CSL hoped to launch the vaccine this year but supplier Merck has experienced prolonged supply constraints.

A CSL spokesperson said Merck was overcoming the problem in the US and “expects to be in a position to maintain supply for a government-funded program from 2014”. It will require Cabinet approval before listing on the NIP due to its high cost.

Associate Professor Kristine Macartney, from the National Centre for Immunisation

Latest

Trending